Home > Treatment Options > Tumor Suppressors > Clinical Trials >

Tanezumab (RN624)

Last Updated: 04/12/21

Status: Schwannomatosis Clinical Trial

Location: Massachusetts General Hospital
Brand: Pfizer
Alt Name: RN624
Drug Description: May Control Schwannoma tumors and Chromic Pain.
  1. "Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis" clinicaltrials.gov https://clinicaltrials.gov/ct2/show/NCT04163419
  2. "FDA Considers Tanezumab Application for Chronic OA Pain." The Rheumatologist https://www.the-rheumatologist.org/article/fda-considers-tanezumab-application-for-chronic-oa-pain/
  3. "U.S. FDA Accepts Regulatory Submission for Tanezumab, a Potential First-in-Class Treatment for Patients with Chronic Pain Due to Moderate-to-Severe Osteoarthritis". https://investor.lilly.com/news-releases/news-release-details/us-fda-accepts-regulatory-submission-tanezumab-potential-first
  4. "Pharmacology of nerve growth factor and discovery of tanezumab, an anti-nerve growth factor antibody and pain therapeutic" Pharmacological research, 2020 - Elsevier https://www.sciencedirect.com/science/article/abs/pii/S1043661819305912
What is NF2? | About Us | Treatment Options | Sitemap

Site Search

Disclaimer: Neurofibromatosis Type 2 - Information and Services, www.nf2is.org, is not run by medical experts, affiliated with any healthcare organization or any other company. No assurance can be made to the accuracy or completeness of the information provided here, the accuracy of other sites to which this site links, or of sites that link to this site. - Read More

Copyright © 2021